People S United Financial Inc. Cuts Position in Novartis AG (NYSE:NVS)
People S United Financial Inc. Cuts Position in Novartis AG (NYSE:NVS)
People s United Financial Inc. lessened its holdings in Novartis AG (NYSE:NVS – Get Rating) by 3.7% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 35,064 shares of the company's stock after selling 1,341 shares during the quarter. People s United Financial Inc.'s holdings in Novartis were worth $3,077,000 at the end of the most recent quarter.
人民聯合金融股份有限公司在最近向美國證券交易委員會披露的信息中稱，今年第一季度，該公司減持了3.7%的諾華製藥股份。該公司在本季度出售了1,341股後，持有35,064股該公司股票。截至最近一個季度末，People‘s United Financial Inc.持有的諾華股份價值3,077,000美元。
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Atwood & Palmer Inc. lifted its stake in shares of Novartis by 400.0% in the first quarter. Atwood & Palmer Inc. now owns 375 shares of the company's stock worth $33,000 after buying an additional 300 shares in the last quarter. Allegheny Financial Group LTD purchased a new stake in Novartis during the fourth quarter valued at approximately $34,000. DeDora Capital Inc. purchased a new stake in Novartis during the first quarter valued at approximately $34,000. Tyler Stone Wealth Management purchased a new stake in shares of Novartis in the fourth quarter worth $39,000. Finally, Crewe Advisors LLC increased its stake in shares of Novartis by 678.0% in the fourth quarter. Crewe Advisors LLC now owns 459 shares of the company's stock worth $40,000 after purchasing an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 9.40% of the company's stock.
許多其他對衝基金和其他機構投資者也買賣了該公司的股票。今年第一季度，阿特伍德-帕爾默公司增持的諾華股份增加了400.0%。Atwood&Palmer Inc.現在持有375股該公司股票，價值33,000美元，上個季度又購買了300股。阿勒格尼金融集團有限公司在第四季度購買了諾華公司的新股份，價值約3.4萬美元。DeDora Capital Inc.在第一季度購買了諾華公司的新股份，價值約3.4萬美元。泰勒·斯通財富管理公司在第四季度購買了價值3.9萬美元的諾華新股。最後，Crewe Advisors LLC在第四季度增持了678.0%的諾華股份。Crewe Advisors LLC現在持有該公司459股股票，價值4萬美元，上個季度又購買了400股。對衝基金和其他機構投資者持有該公司9.40%的股份。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Several research firms recently weighed in on NVS. UBS Group raised their target price on shares of Novartis from CHF 85 to CHF 88 and gave the company a "neutral" rating in a research note on Wednesday, April 27th. Oppenheimer lowered shares of Novartis from an "outperform" rating to a "market perform" rating in a report on Friday, June 3rd. JPMorgan Chase & Co. raised their target price on shares of Novartis from CHF 80 to CHF 81 and gave the company an "underweight" rating in a research report on Wednesday, July 20th. Credit Suisse Group lifted their price objective on shares of Novartis from CHF 85 to CHF 88 in a research report on Thursday, April 28th. Finally, Wolfe Research cut shares of Novartis from an "outperform" rating to a "market perform" rating in a research note on Monday, May 9th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $87.33.
幾家研究公司最近對NVS發表了看法。瑞銀集團在4月27日星期三的一份研究報告中將諾華公司的股票目標價從85瑞士法郎上調至88瑞士法郎，並給予該公司“中性”評級。在6月3日星期五的一份報告中，奧本海默將諾華公司的股票評級從“跑贏大盤”下調至“市場表現”。摩根大通在7月20日星期三的一份研究報告中將諾華公司的股票目標價從80瑞士法郎上調至81瑞士法郎，並給予該公司“減持”評級。瑞士信貸集團在4月28日星期四的一份研究報告中將諾華公司的股票目標價從85瑞士法郎上調至88瑞士法郎。最後，沃爾夫研究公司在5月9日星期一的一份研究報告中將諾華公司的股票評級從“跑贏大盤”下調至“市場表現”。兩位研究分析師對該股的評級為賣出，八位分析師給出了持有評級，三位分析師給出了買入評級，一位分析師給出了該公司股票的強力買入評級。根據MarketBeat的數據，該股平均評級為持有，平均目標價為87.33美元。
Novartis Stock Down 0.4 %
諾華公司股價下跌0.4%
Novartis (NYSE:NVS – Get Rating) last announced its quarterly earnings results on Monday, July 18th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.52 by $0.04. The company had revenue of $12.78 billion for the quarter, compared to analyst estimates of $12.78 billion. Novartis had a net margin of 44.31% and a return on equity of 21.88%. The firm's revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.64 earnings per share. As a group, equities research analysts predict that Novartis AG will post 6.06 earnings per share for the current fiscal year.
諾華公司(紐約證券交易所代碼：NVS-GET Rating)上一次公佈季度收益是在7月18日星期一。該公司公佈本季度每股收益為1.56美元，比普遍預期的1.52美元高出0.04美元。該公司本季度營收為127.8億美元，而分析師預期為127.8億美元。諾華的淨利潤率為44.31%，股本回報率為21.88%。該公司的收入同比下降了1.4%。去年同期，該公司公佈的每股收益為1.64美元。作為一個整體，股票研究分析師預測，諾華製藥本財年的每股收益將達到6.06歐元。
About Novartis
諾華公司簡介
(Get Rating)
(獲取評級)
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
諾華製藥在全球研究、開發、製造和營銷保健品。該公司通過兩個部門運營，創新藥品和Sandoz。創新藥品部門為患者和醫療保健提供者提供處方藥。它還提供眼科、神經科學、免疫學、肝科、皮膚科、呼吸科、心血管、腎臟和新陳代謝藥物產品。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- 3 Blowout Earnings Reports That Could Mark Turning Points
- 3 Stocks Set to Lead the Nasdaq Bull Market
- Will CrowdStrike Extend Its Streak Of Topping Earnings Views?
- Skyworks Solutions Is Worth A Look At These Prices
- MarketBeat Podcast: ESG – Profitably Invest Your Values
- 免費獲取StockNews.com關於諾華(Novartis)的研究報告
- 3份井噴式收益報告可能標誌着轉折點
- 3只股票將引領納斯達克牛市
- CrowdStrike是否會延續其盈利排行榜榜首的勢頭？
- Skyworks Solutions值得看看這些價格
- MarketBeat播客：ESG--有利可圖地投資你的價值
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
接受諾華日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對諾華和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。